A year and a half ago, a Chinese company that many oncologists had never heard of wowed the cancer world with impressive early-stage data on its CAR-T cancer therapy in 35 Chinese patients with multiple myeloma. Johnson & Johnson quickly moved to license the therapy, and U.S. patients are starting to be dosed.

Next month, Legend Biotech is headed back into the spotlight. And this time it’s presenting data on 22 additional Chinese patients that raise more questions.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • going through mantle cell lymphoma a second time – the only cartcell clinical trials I found close to me (Oregon) were at oshu but they are no longer taking new patients – anything else close to Oregon that I might be able to do?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy